Overview Dividends

(ZTS) Zoetis - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98978V1035

Vaccines, Parasiticides, Diagnostics, Dermatology, Anti-Infectives

ZTS EPS (Earnings per Share)

EPS Growth (3Y CAGR): 15.27%
EPS Trend (3Y Correlation): 83.0%

ZTS Revenue

Revenue Growth (3Y CAGR): 6.09%
Revenue Trend (3Y Correlation): 86.6%

Risk via 10d forecast
Volatility	53.8%
Value at Risk 5%th	83.1%

Reward
Sharpe Ratio	-1.19
Alpha	-47.73

Character
Hurst Exponent	0.666
Beta	0.962

Drawdowns 3y
Max DD	38.94%
Mean DD	11.35%

Description: ZTS Zoetis September 26, 2025

Zoetis Inc. (NYSE: ZTS) is the world’s largest pure-play animal-health company, covering the full product lifecycle-from discovery and development to manufacturing and commercialization-of medicines, vaccines, diagnostics, biodevices, genetic tests and precision-health solutions for both livestock (cattle, swine, poultry, fish, sheep) and companion animals (dogs, cats, horses).

Its portfolio spans parasiticides, vaccines, dermatology, anti-infectives, pain-management and sedation products, as well as point-of-care diagnostics, laboratory kits, blood-glucose monitors and nutritionals. Sales are directed to veterinarians, livestock producers and pet owners, with a growing emphasis on data-driven precision health tools that can improve animal welfare and farm productivity.

Key recent metrics (FY 2023): revenue of $7.1 billion, up ≈ 7 % YoY; adjusted EBITDA margin of ≈ 30 %; and diluted EPS of $4.65. The company’s growth is being driven by rising global protein demand (FAO projects a 30 % increase in meat consumption by 2050) and accelerating adoption of preventive health regimes in intensive-farming operations, which boost vaccine and diagnostic sales.

Zoetis is also expanding its pipeline through collaborations such as the partnership with Blacksmith Medicines to develop novel animal-health antibiotics, addressing both antimicrobial-resistance concerns and the need for new therapeutic classes.

For a deeper quantitative assessment, you might explore ValueRay’s detailed valuation models for ZTS.

ZTS Stock Overview

Market Cap in USD	52,989m
Sub-Industry	Pharmaceuticals
IPO / Inception	2013-02-01
Return 12m vs S&P 500	-39.02%
Analyst Rating	4.26 of 5

ZTS Dividends

Dividend Yield	1.66%
Yield on Cost 5y	1.27%
Yield CAGR 5y	21.23%
Payout Consistency	100.0%
Payout Ratio	32.3%

ZTS Growth Ratios

CAGR	-5.85%
CAGR/Max DD Calmar Ratio	-0.15
CAGR/Mean DD Pain Ratio	-0.52
Current Volume	5808.8k
Average Volume	2958.4k

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (2.65b TTM) > 0 and > 6% of Revenue (6% = 563.8m TTM)

FCFTA 0.15 (>2.0%) and ΔFCFTA -1.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 50.82% (prev 50.04%; Δ 0.78pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.19 (>3.0%) and CFO 2.92b > Net Income 2.65b (YES >=105%, WARN >=100%)

Net Debt (5.19b) to EBITDA (4.05b) ratio: 1.28 <= 3.0 (WARN <= 3.5)

Current Ratio 3.64 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (443.2m) change vs 12m ago -2.27% (target <= -2.0% for YES)

Gross Margin 70.63% (prev 68.49%; Δ 2.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 63.67% (prev 63.75%; Δ -0.07pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 15.42 (EBITDA TTM 4.05b / Interest Expense TTM 231.0m) >= 6 (WARN >= 3)

Altman Z'' 7.99

(A) 0.32 = (Total Current Assets 6.58b - Total Current Liabilities 1.81b) / Total Assets 15.16b

(B) 0.90 = Retained Earnings (Balance) 13.59b / Total Assets 15.16b

warn (B) unusual magnitude: 0.90 — check mapping/units

(D) 1.31 = Book Value of Equity 12.78b / Total Liabilities 9.76b

Total Rating: 7.99 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 88.02

1. Piotroski 6.50pt = 1.50

2. FCF Yield 3.85% = 1.93

3. FCF Margin 23.84% = 5.96

4. Debt/Equity 1.35 = 1.66

5. Debt/Ebitda 1.28 = 1.34

6. ROIC - WACC (= 17.16)% = 12.50

7. RoE 53.56% = 2.50

8. Rev. Trend 86.59% = 6.49

9. EPS Trend 83.00% = 4.15

What is the price of ZTS shares?

As of November 10, 2025, the stock is trading at USD 120.24 with a total of 5,808,839 shares traded.
Over the past week, the price has changed by -16.70%, over one month by -15.85%, over three months by -19.03% and over the past year by -30.83%.

Is Zoetis a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Zoetis (NYSE:ZTS) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 88.02 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ZTS is around 103.83 USD . This means that ZTS is currently overvalued and has a potential downside of -13.65%.

Is ZTS a buy, sell or hold?

Zoetis has received a consensus analysts rating of 4.26. Therefore, it is recommended to buy ZTS.

Strong Buy: 10
Buy: 4
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ZTS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	175	45.5%
Analysts Target Price	175	45.5%
ValueRay Target Price	115.6	-3.9%

ZTS Fundamental Data Overview November 10, 2025

Market Cap USD = 52.99b (52.99b USD * 1.0 USD.USD)
P/E Trailing = 20.2424
P/E Forward = 21.692
P/S = 5.6389
P/B = 13.0444
P/EG = 2.1909
Beta = 0.962
Revenue TTM = 9.40b USD
EBIT TTM = 3.56b USD
EBITDA TTM = 4.05b USD
Long Term Debt = 5.22b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.35b USD (from shortTermDebt, last fiscal year)
Debt = 7.27b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.19b USD (from netDebt column, last quarter)
Enterprise Value = 58.18b USD (52.99b + Debt 7.27b - CCE 2.08b)
Interest Coverage Ratio = 15.42 (Ebit TTM 3.56b / Interest Expense TTM 231.0m)
FCF Yield = 3.85% (FCF TTM 2.24b / Enterprise Value 58.18b)
FCF Margin = 23.84% (FCF TTM 2.24b / Revenue TTM 9.40b)
Net Margin = 28.21% (Net Income TTM 2.65b / Revenue TTM 9.40b)
Gross Margin = 70.63% ((Revenue TTM 9.40b - Cost of Revenue TTM 2.76b) / Revenue TTM)
Gross Margin QoQ = 71.54% (prev 72.28%)
Tobins Q-Ratio = 3.84 (Enterprise Value 58.18b / Total Assets 15.16b)
Interest Expense / Debt = 0.80% (Interest Expense 58.0m / Debt 7.27b)
Taxrate = 18.71% (166.0m / 887.0m)
NOPAT = 2.90b (EBIT 3.56b * (1 - 18.71%))
Current Ratio = 3.64 (Total Current Assets 6.58b / Total Current Liabilities 1.81b)
Debt / Equity = 1.35 (Debt 7.27b / totalStockholderEquity, last quarter 5.40b)
Debt / EBITDA = 1.28 (Net Debt 5.19b / EBITDA 4.05b)
Debt / FCF = 2.32 (Net Debt 5.19b / FCF TTM 2.24b)
Total Stockholder Equity = 4.95b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.49% (Net Income 2.65b / Total Assets 15.16b)
RoE = 53.56% (Net Income TTM 2.65b / Total Stockholder Equity 4.95b)
RoCE = 35.02% (EBIT 3.56b / Capital Employed (Equity 4.95b + L.T.Debt 5.22b))
RoIC = 25.45% (NOPAT 2.90b / Invested Capital 11.38b)
WACC = 8.29% (E(52.99b)/V(60.26b) * Re(9.34%) + D(7.27b)/V(60.26b) * Rd(0.80%) * (1-Tc(0.19)))
Discount Rate = 9.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.85%
[DCF Debug] Terminal Value 76.59% ; FCFE base≈2.27b ; Y1≈2.67b ; Y5≈4.09b
Fair Price DCF = 126.0 (DCF Value 55.51b / Shares Outstanding 440.7m; 5y FCF grow 18.89% → 3.0% )
EPS Correlation: 83.00 | EPS CAGR: 15.27% | SUE: 0.96 | # QB: 3
Revenue Correlation: 86.59 | Revenue CAGR: 6.09% | SUE: -0.14 | # QB: 0

Additional Sources for ZTS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle